

Patient:
 DOB: Age: Sex:
 Patient Identifiers:
 Visit Number (FIN):

Client:
 Physician:

ARUP Test Code: 2013716
 Collection Date:
 Received in lab:
 Completion Date:

Risk Category

LDL Particle Number	nmol/L	Optimal	Near Optimal	Borderline High	High	Very High
		<=1136	>1136-1449	1450-1764	1765-2186	>2186
		684				

LDL Cholesterol (calculated)	mg/dL	Optimal	Near Optimal	Borderline High	High	Very High
		<100	100-129	130-159	160-189	>=190
		91				

HDL Cholesterol	mg/dL	Optimal	Near Optimal	Undesirable
		>=60	59-40	<40
		68		

Triglycerides	mg/dL	Normal	Borderline High	High	Very High
		<150	150-199	200-499	>=500
		131			

Total Cholesterol	mg/dL	Optimal	Borderline High	Undesirable
		<200	200-239	>=240
		185		

Small LDL Particle Number	nmol/L	Optimal	Near Optimal	Borderline High	High
		<220	220-634	635-949	>949
		377			

LDL Size	nm	Optimal	Near Optimal	Borderline High	High
		>22.5	22.5-20.8	20.7-19.6	<19.6
		21.1			

Large VLDL Particle Number	nmol/L	Optimal	Near Optimal	Borderline High	High
		<0.9	0.9-2.7	2.8-7.0	>7.0
		3.6			



Patient:
 ARUP Accession: 23-118-139326

LipoFit by NMR

Patient: | Date of Birth: | Sex: | Physician:
 Patient Identifiers: | Visit Number (FIN):

VLDL Size	nm	Optimal	Near Optimal	Borderline High	High
		<44.3	44.3-46.7	46.8-50.2	>50.2
		48.4			
HDL Particle Number	umol/L	Optimal	Near Optimal	Borderline High	High
		>36.8	36.8-33.1	33.0-29.7	<29.7
		40.6			
Large HDL Particle Number	umol/L	Optimal	Near Optimal	Borderline High	High
		>7.3	7.3-4.4	4.3-2.0	<2.0
		8.9			
HDL Size	nm	Optimal	Near Optimal	Borderline High	High
		>9.3	9.3-8.9	8.8-8.6	<8.6
		9.5			

Test Information

Small LDL Particle Number and LDL Particle Size are associated with CVD risk, but not after LDL Particle Count is taken into account.

Reference intervals for the measurements of particle counts and sizes from Nuclear Magnetic Resonance (NMR) spectroscopy are currently only available for adults of 18 years of age and older.

Interpretive data for LDL Cholesterol, HDL Cholesterol, Triglycerides, and Total Cholesterol are based on NCEP ATP III guidelines and are intended for use in adults. For interpretive guidance for pediatric patients, please visit www.aruplab.com.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

